)
Visual24 Oct 2025
Meta's volatility
Nykode Therapeutics (NYKD) investor relations material
Nykode Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary27 Aug, 2025
Executive summary
Achieved net profit of $0.9 million in Q2 2025, reversing a net loss of over $7.3 million in Q2 2024, driven by significant cost reductions and organizational streamlining.
Revenue and other income declined to $0.2 million from $0.6 million year-over-year, mainly due to the termination of Genentech and Regeneron agreements.
Strategic focus centers on VB-ten 16/VB10.16 for head and neck cancer, VB-ten neo/VB10.NEO individualized neoantigen therapy, and an antigen-specific immune tolerance platform for autoimmune diseases.
Completed organizational restructuring and pipeline prioritization to maximize value and streamline costs.
Susanne Staphos/Stuffers elected Chair of the Board at the April 2025 Extraordinary General Assembly.
Financial highlights
Q2 2025 revenue and other income totaled $0.2 million, down from $0.6 million in Q2 2024, mainly due to reduced revenue from Genentech and Regeneron.
Operating expenses decreased to $6.9 million from $12.4 million year-over-year, reflecting organizational streamlining and reduced clinical activity.
Net profit of $0.9 million in Q2 2025, compared to a net loss of over $7.3 million in Q2 2024, driven by lower expenses and unrealized currency gains.
Cash position at quarter-end was $70 million as of June 30, 2025.
Cash dividend of $32.3 million (NOK1 per share) paid in June 2025.
Outlook and guidance
Cash runway expected to last into 2028, with potential extension to 2029 pending a positive tax case outcome.
No significant growth in organizational or cost base anticipated; focus remains on cost discipline and milestone-driven investments.
Interim analysis for the ABILITY trial (VB-ten 16/VB10.16) expected in 2027, within the current cash runway.
VB10.NEO positioned to attract partners after key peer data readouts within 18 months.
Continued investment in the immune tolerance/ASIT platform for autoimmune indications and partnerships.
Regeneron collaboration status and implications?
VB10.NEO partnership strategy post-peer data?
Update on pending tax case and cash runway impact?
Abili-T trial: Key operational next steps and timeline
VB10.NEO: Capitalize on peer INT readouts
Regeneron collaboration: Current status and outlook
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Nykode Therapeutics earnings date
Q3 202526 Nov, 2025
Next Nykode Therapeutics earnings date
Q3 202526 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company based in Oslo, Norway. The company focuses on the discovery and development of novel vaccines and immunotherapies, primarily targeting cancer and infectious diseases. Nykode leverages its proprietary modular vaccine technology, which directs antigens to antigen-presenting cells, aiming to induce strong and long-lasting immune responses. Its leading product candidates include VB10.16, a therapeutic vaccine in development for human papillomavirus (HPV)-related cancers, and VB10.NEO, a cancer neoantigen vaccine, which is in clinical trials for several types of advanced tumors. The company is headquartered in Oslo, Norway, and its shares are listed on the Oslo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage